Bionano Genomics, Inc. (NASDAQ:BNGO) Q4 2025 Earnings Call Transcript March 23, 2026 Bionano Genomics, Inc. reports earnings ...

OGM VIA customers represent a meaningful software revenue stream and a natural on-ramp to broader Bionano Genomics, Inc.

The market misinterprets past COVID-era revenue growth for 10x Genomics and fails to integrate current sector growth. Read ...

Attributed Q4 revenue declines to supply constraints from a manufacturing partner for silicon wafers, creating a backlog of ...

Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the fourth quarter and full year ended December 31, 2025. "2025 demonstrated the ...

Bionano Genomics Inc (BNGO) reports improved gross margins and cost management amid revenue declines, with promising growth ...

Te Whatu Ora starts genomics testing pilot. Te Whatu Ora Health New Zealand has launched a two-year pilot to deliver local ...

Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the fourth quarter and full year ended December 31, 2025. "2025 demonstrated the momentum we built as a business,” commented ...

Good day, and welcome to the Bionano Fourth Quarter and Full Year 2025 Earnings Conference Call. Today's conference is being recorded. At this time, I would like to turn the conference over to Webb ...

The growing investing icon was skimpy on her purchases last week, making the names she did buy that much more interesting.

Bionano Genomics BNGO just pulled back the curtain on its fourth-quarter results, and the message is clear: the company is ...

Microscopic images of human tissue are a cornerstone of biomedical research and clinical diagnostics. Yet despite their ...